tiprankstipranks
Trending News
More News >

Invion’s Skin Cancer Trial Shows Promising Results with INV043

Story Highlights
Invion’s Skin Cancer Trial Shows Promising Results with INV043

Confident Investing Starts Here:

Invion ( (AU:IVX) ) just unveiled an announcement.

Invion Limited announced positive findings from the Safety Review Committee regarding its Phase I/II non-melanoma skin cancer trial using INV043. The trial showed no adverse events and indicated a reduction in lesion size post-treatment, with patients experiencing no pain, a significant advantage over existing treatments. The trial also highlighted INV043’s potential as a diagnostic tool, with cancer cells fluorescing under violet light, aiding in more precise surgical interventions. These findings support the continuation of the trial and contribute to the upcoming anogenital cancer trial in collaboration with the Peter MacCallum Cancer Centre.

More about Invion

Invion Limited operates in the biotechnology industry, focusing on developing innovative treatments for cancer. The company is known for its lead drug candidate, INV043, which is used in the treatment of non-melanoma skin cancer and other cancer types.

Average Trading Volume: 82,664

Technical Sentiment Signal: Sell

Current Market Cap: A$7.37M

See more data about IVX stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App